KW-0761 (mogamulizumab)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Apr 1, 2012 → May 1, 2015
NCT ID
NCT01611142About KW-0761 (mogamulizumab)
KW-0761 (mogamulizumab) is a phase 2 stage product being developed by Kyowa Kirin for Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01611142. Target conditions include Peripheral T-Cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01611142 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma